Hepatic de novo lipogenesis is suppressed and fat oxidation is increased by omega-3 fatty acids at the expense of glucose metabolism

Charlotte J Green,1 Camilla Pramfalk,1 Catriona A Charlton,1 Pippa J Gunn,1 Thomas Cornfield,1 Michael Pavlides,1,2 Fredrik Karpe,1,3 Leanne Hodson1,3

ABSTRACT

Objective Increased hepatic de novo lipogenesis (DNL) is suggested to be an underlying cause in the development of nonalcoholic fatty liver disease and/or insulin resistance. It is suggested that omega-3 fatty acids (FA) lower hepatic DNL. We investigated the effects of omega-3 FA supplementation on hepatic DNL and FA oxidation using a combination of human in vivo and in vitro studies.

Research design and methods Thirty-eight healthy men were randomized to take either an omega-3 supplement (4 g/day eicosapentaenoic acid (EPA)+docosahexaenoic acid (DHA) as ethyl esters) or placebo (4 g/day olive oil) and fasting measurements were made at baseline and 8 weeks. The metabolic effects of omega-3 FAs on intrahepatocellular triacylglycerol (IHTAG) accumulation due to dietary FA oxidation and fasting and postprandial plasma glucose concentrations increased after supplementation with omega-3 fatty acids.

Results Fasting plasma TAG concentrations significantly decreased in the omega-3 group and remained unchanged in the placebo group. Eight weeks of omega-3 supplementation significantly decreased IHTAG, fasting and postprandial hepatic DNL, while significantly increasing dietary FA oxidation and fasting and postprandial plasma glucose concentrations. In vitro studies supported the in vivo findings of omega-3 FAs (EPA+DHA) decreasing hepatic DNL and increasing FA oxidation and plasma glucose concentrations. Attenuation of hepatic DNL may be considered advantageous; however, consideration is required as to what the potential excess of nonlipid substrates (eg, glucose) will have on intrahepatic metabolism away from FA esterification toward oxidation.

Conclusions Omega-3 supplementation had a potent effect on decreasing hepatic DNL and increasing FA oxidation and plasma glucose concentrations. Attenuation of hepatic DNL may be considered advantageous; however, consideration is required as to what the potential excess of nonlipid substrates (eg, glucose) will have on intrahepatic and extrahepatic metabolic pathways.

Trial registration number NCT01936779.

INTRODUCTION

Nonalcoholic fatty liver disease (NAFLD), defined as excess intrahepatocellular triacylglycerol (IHTAG) accumulation due to nonalcoholic causes, is a complication in individuals who are obese and/or have type 2 diabetes (T2D). Increased hepatic de novo lipogenesis (DNL) is often suggested to be an underlying cause in the development of NAFLD and/or insulin resistance. Observational studies have reported fasting hepatic DNL to be higher in individuals with NAFLD compared with those without. It has been suggested that changes in plasma
TAG concentrations are proportional to the amount of hepatic DNL.\(^5\)

Supplementation with the marine-derived omega-3 fatty acids (FAs), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), in doses of ≥3 g/day significantly decrease plasma TAG concentrations\(^6\) and can reduce IHTAG content.\(^7\) In vitro cellular and animal models have proposed the mechanisms by which this is achieved include downregulation of lipogenic and upregulation of β-oxidation pathways via hepatic transcription factors.\(^7\) In line with omega-3 FAs upregulating β-oxidation, some\(^8\) but not all\(^9\) have reported an increase in fat oxidation, when assessed by indirect calorimetry. However, few have assessed the effect of omega-3 FAs on fasting and postprandial hepatic DNL and FA oxidation, simultaneously, in vivo, in humans.

The effects of omega-3 supplementation on markers of glycemia are inconsistent. For example, Logan et al\(^6\) reported no change in older, overweight/obese females taking 3 g EPA+DHA for 12 weeks, while others report increased fasting plasma glucose concentrations in individuals with T2D taking 20 mL fish oil for 9 weeks\(^9\) or 5 g EPA+DHA for 24 weeks\(^10\); in one case, a decrease was reported in overweight/obese adults with impaired glucose tolerance taking 3 g EPA+DHA for 18 months.\(^11\)

The disparity in findings is likely related to the dose and duration of omega-3 supplementation along with the clinical status of the individuals studied. In a pilot study, we previously found supplementation with 4 g/day EPA+DHA for 15–18 months in individuals with NAFLD did not alter fasting plasma glucose concentrations, but decreased fasting hepatic DNL and increased plasma 3-hydroxybutyrate (3OHB) concentrations.\(^12\) Therefore, the aim of this work was to extend our previous observations and investigate the effect of 8 weeks of EPA+DHA (omega-3) supplementation on fasting and postprandial hepatic DNL and FA oxidation using a combination of human in vivo and in vitro models and stable-isotope tracer methodology.

**RESEARCH DESIGN AND METHODS**

**In vivo human studies**

Healthy male participants, with fasting plasma TAG concentrations 1.5 mmol/L or greater were recruited from the Oxford BioBank (OBB).\(^13\) All volunteers were non-diabetic and free from any known disease, had a body mass index <35 kg/m\(^2\), were not taking medication known to affect lipid or glucose metabolism, did not smoke, did not consume alcohol above recommended limits\(^14\) and were not taking any supplements enriched with omega-3 FAs.

**Study design, randomization and supplementation**

A total of 57 men (aged 35–55 years) were screened with 47 meeting the inclusion criteria. Participants were randomly assigned to consume either omega-3 FA ethyl esters (4 g/day, n=24) or placebo (4 g/day, n=23) and were studied before and 8 weeks after supplementation (online supplementary figure 1). Participants randomized to the omega-3 FA group consumed 4×1 g capsules/day with each capsule containing 460 mg EPA ethyl ester and 380 mg DHA ethyl ester (a total of 1.84 g EPA+1.52 g DHA/day (medicinal product name Omacer/Lovaza)). Participants randomized to the placebo group consumed 4×1 g capsules/day with each capsule containing olive oil (FA composition oleic acid ~67%, palmitic acid ~15%, linoleic acid ~15% and stearic acid ~2%, alpha linolenic acid ~1%). This was an open-label study and the dose of 4 g/day was based on previous studies\(^10\)\(^,\)\(^16\)\(^,\)\(^17\) and olive oil was chosen as a placebo as oleic acid is a commonly consumed FA due to its ubiquitous nature in foods\(^18\) and has been used previously.\(^10\)\(^,\)\(^16\)\(^,\)\(^17\) Both the omega-3 and placebo were administrated as 1 g, soft red-brown, gelatin shelled capsules and participants were encouraged to take the supplement with the first meal of the day. Supplements (omega-3 and placebo) were provided by Pronova Biopharma (now part of BASF) (Pronova Biopharma ASA, Lysaker, Norway).

We determined the 90th percentile of plasma TAG concentrations for males in the OBB was 2.2 mmol/L (SD of 0.5 mmol/L). Based on the work of Chan et al\(^19\)\(^,\)\(^20\) who reported a 25% decrease in plasma TAG, in males after 6 weeks of omega-3 FA supplementation (4 g/day EPA+DHA), we predicted a 20% decrease in plasma TAG after 8 weeks supplementation with 4 g/day of omega-3 FA. The number of individuals required to detect a 20% decrease in plasma TAG, with a power of 0.80 and α of 0.05, was n=21. The supplementation period of 8 weeks was based on the work of Cussons et al\(^17\).

Whole body composition and fat distribution were measured using dual-energy X-ray absorptiometry\(^21\) at the baseline visit.

**Placebo group**

Of the 23 individuals randomized, 4 did not complete the study due to changes in personal and/or working circumstances, therefore giving complete data for 19 individuals (online supplementary figure 1). Participants came in to the Clinical Research Unit after an overnight fast for the baseline visit. Participants randomized to the placebo group consumed 4×1 g capsules/day with each capsule containing olive oil (a total of 1.84 g/day). Supplements (omega-3 and placebo) were provided by Pronova Biopharma (now part of BASF) (Pronova Biopharma ASA, Lysaker, Norway).

**Omega-3 supplementation group**

Of the 24 participants randomized, 3 did not complete the study due to changes in personal and/or working circumstances leaving 21 participants for whom we had fasting data. As we wanted to investigate the effect of omega-3 FAs on hepatic DNL and FA partitioning, only participants in this group had IHTAG measured and underwent postprandial study days. From this, we have complete data for 19 individuals as two individuals did not complete the second postprandial study day due to difficulties in obtaining blood samples over the course of the study day (online supplementary figure 1).
Compliance
To assess compliance of participants to taking the supplements erythrocyte FA composition was assessed by centrifugation at 4°C for the measurement of plasma metabolite and insulin concentrations as described. Separation of the chylomicron fraction (Svedberg flotation rate, S >400) and the very low-density lipoprotein (VLDL)-rich fraction (S 20–400) were made by sequential flotation using density gradient ultracentrifugation and anti-ApoB100 immunoabsorption capture to obtain a fraction completely devoid of apoB48 and hereafter called VLDL, as described. 25

Measurement of IHTAG content (omega-3 group only)
IHTAG content was measured using proton magnetic resonance spectroscopy within 1 week of the metabolic study day, at baseline and after 8 weeks of omega-3 FA supplementation as described. 23

Metabolic study day (omega-3 group only)
Prior to the study day, subjects were asked to avoid foods naturally enriched in 13C (eg, cornflakes, popcorn, foods made with corn starch and so on), alcohol and strenuous exercise. The evening prior to the study day, subjects consumed deuterated water (2H2O) (3 g/kg body water) and continued to consume 2H2O during the course of the study day for the measurement of fasting and post-prandial hepatic DNL. 24

On the study day, after an overnight fast and consumption of 2H2O, subjects came to the Clinical Research Unit and a cannula was inserted into an antecubital vein and baseline (Time 0) blood and breathe samples taken. Participants were then fed a mixed test meal, consisting of 40 g Rice Krispies (Kellogs, Manchester, UK), 200 g skimmed milk and a chocolate drink containing 40 g olive oil (40 g fat, 40 g carbohydrate). Two hundred mg of [U13C]palmitic acid was emulsified with the chocolate drink to trace the fate of the dietary FAs. Repeated blood and breathe samples were taken over the course of the study period.

Indirect calorimetry was performed at Time 0 (fasting) and then 120 min after consumption of the test meal using a GEM calorimeter (GEMNutrition, Daresbury, Cheshire, UK) to determine whole-body CO2 production, whole-body respiratory exchange ratio and substrate utilization rates.

Analytical methods
Whole blood was collected into heparinized syringes (Sarstedt, Leicester, UK) and plasma was rapidly separated by centrifugation at 4°C for the measurement of plasma metabolite and insulin concentrations as described. 25 Separation of the chylomicron fraction (Svedberg flotation rate, S >400) and the very low-density lipoprotein (VLDL)-rich fraction (S 20–400) were made by sequential flotation using density gradient ultracentrifugation and anti-ApoB100 immunoabsorption capture to obtain a fraction completely devoid of apoB48 and hereafter called VLDL, as described. 25

Samples were taken at Time 0 (baseline) and then 30, 60, 90, 120, 180, 240, 300 and 360 min after the consumption of the test meal for the measurement of plasma glucose, insulin, TAG, nonesterified fatty acids (NEFA), 3OHB and at 0, 15, 30, 60, 90, 120, 180, 240, 300 and 360 min for the analysis of chylomicron-TAG, TAG-rich lipoproteins-TAG and 0, 180, 240, 300 and 360 min for the analysis of VLDL-TAG. Breath samples were collected at 0, 60, 90, 120, 180, 240, 300 and 360 min into EXETAINER tubes (Labco, High Wycombe, Bucks, UK) for measurement of expired 13CO2 enrichment.

FA and isotopic enrichment
To determine the specific FA composition and isotopic enrichment, total lipids were extracted from plasma and lipoproteins. FA methyl esters were prepared from plasma NEFA, and TAG fractions, along with erythrocyte total phospholipids as described. 22 The FA compositions (μmol/100 μmol total FA) in these fractions were determined by gas chromatography (GC) and in plasma NEFA and TAG fractions palmitate concentrations were calculated as described. 25

[U13C]palmitate enrichments were measured in plasma NEFA, TAG, S >400 (chylomicron-TAG), S 20–400-TAG and VLDL-TAG FA methyl ester derivatives using a Delta Plus XP GC-combustion isotope ratio mass spectrometer (Thermo electron, Bremen, Germany). 25 The tracer-to-trace ratio (TTR) of a baseline measurement (before administration of [U13C]palmitate) was subtracted from the TTR of each sample to account for natural abundance and then multiplied by the corresponding palmitate concentrations to give plasma and lipoprotein tracer concentrations. 25

We estimated dietary FA oxidation at the whole-body and hepatic level. By collecting breath samples relative rate of whole-body meal-derived FA oxidation were calculated as described. 26 The liver is the only organ to produce urea in significant amounts and CO2 produced from hepatic FA oxidation is used in urea synthesis. 27 We used stable-isotope methodologies to measure 13CO2/12CO2 ratios liberated from plasma urea, based on the method of Kloppenburg et al 28 to assess whether recently ingested dietary FAs were undergoing complete intrahepatic oxidation. To allow for sequestration of label into the bicarbonate pool a dietary acetate recovery factor of 51% was applied. 29 Hepatic CO2 production was not measured directly, but calculated using reported splanchic respiratory quotients. 30

Fasting and postprandial hepatic DNL was assessed based on the incorporation of deuterium from 2H2O in plasma water (Finnigan Gas-Bench-II; Thermo Fisher Scientific, Loughborough, UK) into VLDL-TG palmitate using GC–mass spectrometry with monitoring ions with mass-to-charge ratios (m/z) of 270 (M+0) and 271 (M+1) and percentage DNL calculated as described. 31

In vitro cellular studies
All reagents were obtained from Life Technologies (Paisley, Scotland) unless otherwise stated. Fetal bovine serum (FBS) was purchased from Seralab (West Sussex, UK). FAs were purchased from Cambridge Bioscience (Cambridge, UK). FA free bovine serum albumin (BSA), was purchased from SIGMA Aldrich (UK). KAPA probe fast mix was purchased from KAPA Biosystems (London, UK).
Cell culture
Huh7 cells were grown as described.32 Confluent cells were cultured in DMEM (11 mM)+Glutamax, 10% FBS, 1× nonessential amino acids, 1% penicillin-streptomycin, for 48 hours prior to FA treatment. Cells were first treated with 100 µM FA (containing oleic (O, 45%), palmitic (P, 30%) and linoleic (L, 25%) acid (OPL) conjugated to 1.25% FA-free BSA giving a FA:BSA molar ratio of 3:1 for 24 hours. Next, the cells were treated with 200 µM FA (FA:BSA molar ratios of 3:1) mixtures for 48 hours that consisted of either OPL alone (90 µM oleic, 60 µM palmitic and 50 µM linoleic acid or OPL+EP+DHA (49.5 µM oleic, 33 µM palmitic, 27.5 µM linoleic+55 µM EPA+45 µM DHA). EPA and DHA stocks were stored under nitrogen and cells and media were collected on ice for TAG measurement, which was quantified as described.32 RNA extraction was carried out using QIAGEN RNeasy Mini Kit according to manufacturer’s instructions.

FA and isotopic enrichment
To determine the effect of EPA+DHA on the contribution of DNL-derived FA to intracellular TAG, 50% (5.5mM) of media glucose was labeled with [U-13C] for 48 hours. Cells were collected for analysis and the contribution of glucose-derived FA to intracellular TAG determined using GC-mass spectrometry as described.33 To trace the oxidation of exogenous FA, Huh7 cells were treated with OPL and OPL+EP+DHA where palmitate was labeled (100% D31 palmitate) for 48 hours. As a marker of FA oxidation, the appearance of 2H2O (derived from [D31]palmitate) in media was measured, using a Finnigan GasBench-II (ThermoFisher Scientific, UK).34

Quantitative real time PCR
First strand cDNA was synthesized from 0.5 µg total RNA using a High Capacity Reverse Transcription kit. RT-PCR reactions were run on an Applied Biosystems 7900HT machine. Two housekeeping genes were used: tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta and beta-2-microglobulin.

Calculations and statistical methods
Homeostatic model assessment of insulin resistance (HOMA-IR) was calculated.35 Data were analyzed using SPSS for Windows V.22 (SPSS, Chertsey, UK). All data are presented as means±SEM unless otherwise stated. Areas under the curve (AUCs) were calculated by the trapezoid method. AUCs have been divided by the relevant time period to give time-averaged values. All data sets were tested for normality according to the Shapiro-Wilk test. Comparisons between the placebo and omega-3 groups were made using an independent t-test or Mann Whitney U tests for nonparametric data. For comparisons within the groups and after supplementation were made using a students paired t-test or the nonparametric equivalent. Postprandial data were compared using repeated measures analysis of variance, with time and treatment as factors to investigate the change within the omega-3 FA group over time for specific metabolites. Bonferroni posthoc analysis was performed where appropriate to adjust for multiple comparisons. Associations between variables were carried out using Spearman’s rank correlation coefficient. Statistical significance was set at p<0.05.

For in vitro cell studies, data were analyzed using GraphPad Prism 7 software using an independent t-test or Mann Whitney U test for nonparametric data (GraphPad software, La Jolla, USA).

RESULTS
In vivo human study
Participant characteristics
Thirty-eight subjects (19 placebo and 19 omega-3) completed the study. There was no difference in age, weight, body mass index or waist circumference between or within the groups at baseline and after 8 weeks (table 1). There was no difference between the groups in body composition, which was assessed at the baseline visit with total fat, lean and visceral fat masses being 26.3±1.5 kg vs 27.6±1.9 kg, 60.8±1.6 kg vs 60.5±1.6 kg and 1.7±0.1 kg vs 1.8±0.2 kg, placebo vs omega-3, respectively. Between baseline and 8 weeks fasting plasma TAG and ALT concentrations significantly (p<0.01) decreased, while plasma glucose significantly (p<0.05) increased in the omega-3 group while between the groups the only significant (p<0.05) difference was the change in plasma TAG and ALT concentrations (table 1).

Compliance
Compared with the placebo group, there was a significant (p<0.05) increase in erythrocyte EPA, docosapentaenoic acid (DPA) and DHA in the omega-3 group between baseline and 8 weeks (table 1). Within the omega-3 group, there was a graded response in erythrocyte EPA content ranging from 69% to 537% and the relative change in erythrocyte DHA content was from a small decrease of −6% to an increase of 24%. There was a strong inverse association between baseline levels of erythrocyte EPA and the per cent change in EPA achieved (r=−0.73, p<0.001) while there was no association between baseline erythrocyte DHA levels and per cent change in DHA (r=−0.28, p=NS).

The effect of omega-3 supplementation on IHTAG and plasma postprandial metabolites (omega-3 group only)
Eight weeks of omega-3 supplementation significantly (p<0.05) decreased IHTAG by 19% (table 2). The increase (p<0.05) in fasting plasma glucose concentrations at 8 weeks was maintained after consumption of the mixed test meal (time-averaged 180 min AUC, 5.9±0.2 mmol/L vs 6.3±0.2 mmol/L, baseline vs 8 weeks, p<0.05) and when considered over 360 min, there was a tendency (p=0.058) for higher fasting plasma glucose concentrations at 8 weeks compared with baseline (figure 1A). Omega-3 supplementation had no effect on postprandial plasma insulin (figure 1B) nor systemic NEFA (table 2)
Table 1 Characteristics of study participants at baseline and 8 weeks

<table>
<thead>
<tr>
<th></th>
<th>Placebo (n=19)</th>
<th>Omega-3 (n=19)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Baseline 8 weeks</strong></td>
<td><strong>Change (%)</strong></td>
<td><strong>Baseline 8 weeks</strong></td>
</tr>
<tr>
<td>Age (years)</td>
<td>45 (33–52)</td>
<td>45 (27–52)</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>91 (74–117)</td>
<td>91 (74–115)</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>27.6 (22.0–35.1)</td>
<td>27.8 (21.6–34.6)</td>
</tr>
<tr>
<td>Waist (cm)</td>
<td>100 (86–116)</td>
<td>99 (87–114)</td>
</tr>
<tr>
<td>Hip (cm)</td>
<td>103 (93–113)</td>
<td>103 (94–113)</td>
</tr>
<tr>
<td>HOMA-IR</td>
<td>3.2±0.3</td>
<td>3.3±0.3</td>
</tr>
</tbody>
</table>

| **Fasting plasma biochemical parameters** |                        |                      |
| Glucose (mmol/L)        | 5.4±0.1        | 5.5±0.1            | 1.9±2.0        |
| Insulin (mU/L)          | 13.4±1.0      | 13.2±1.0           | 0.3±5.0        |
| NEFA (µmol/L)           | 388±30        | 389±33             | 6.6±12.0       |
| Total cholesterol (mmol/L) | 5.6±0.2 | 5.5±0.2            | −0.2±5.5       |
| HDL cholesterol (mmol/L) | 1.23±0.06 | 1.24±0.05          | 0.5±2.4        |
| Non-HDL cholesterol (mmol/L) | 4.6±0.2 | 4.2±0.2            | −3.3±7.7       |
| TAG (mmol/L)            | 2.2±0.2       | 2.2±0.2            | 2.6±0.7        |
| ALT (IU/L)              | 51±9          | 61±8               | 39±32          |
| Erythrocyte fatty acids (mol%) |            |                      |
| EPA (20:5 n-3)          | 1.1±0.1       | 1.1±0.1            | −1.4±3.4       |
| DPA (22:5 n-3)          | 5.7±0.2       | 5.6±0.2            | −0.8±1.3       |
| DHA (22:6 n-3)          | 8.3±0.3       | 8.2±0.3            | −1.8±1.2       |

Data expressed as median (min–max) or mean±SEM. Change (%) expressed as mean±SEM. *P<0.05, **p<0.01, ***p<0.001 baseline vs 8 weeks within the group. †P<0.05, ††p<0.01, †††p<0.001% change in placebo vs omega-3 group. ALT, alanine transaminase; BMI, body mass index; DHA, docosahexaenoic acid; DPA, docosapentaenoic acid; EPA, eicosapentaenoic acid; HDL, high density lipoprotein; HOMA-IR, homeostatic model assessment of insulin resistance; NEFA, nonesterified fatty acids; TAG, triacylglycerol.

Concentrations. The significant (p<0.01) decrease in fasting plasma TAG concentrations after omega-3 supplementation were maintained over the course of the postprandial period (figure 1C), which can in part be explained by a significant decrease in fasting and postprandial VLDL-TAG concentrations (table 2). Although there was no change in VLDL-apolipoprotein (Apo) B concentrations with omega-3 supplementation, there was a significant decrease in the VLDL-TAG to VLDL-ApoB ratio, suggesting a decrease in particle size due to lower TAG content, rather than a decrease in particle number (table 2). We correlated the changes from baseline to 8 weeks for IHTAG and VLDL-TAG to VLDL-ApoB ratio and found a positive association (r=−0.54, p<0.05) (online supplementary figure 2). There was no change in postprandial plasma 3OHB concentrations after omega-3 supplementation (table 2).

Supplementation with omega-3 FA resulted in a 30% decrease (p<0.05) in fasting and postprandial hepatic DNL (figure 1D). There was no association between changes in DNL (fasting or postprandial) with change in IHTAG or plasma TAG concentrations (online supplementary figure 2).

The effects of omega-3 supplementation on 13C dietary FA metabolism (omega-3 group only)

There was a significant (p<0.05) decrease in the appearance of 13C (from dietary fat) into chylomicron-TAG but not VLDL-TAG while whole-body and hepatic 13CO2 production significantly (p<0.05) increased after omega-3 supplementation (table 2). There was a significant increase in the respiratory exchange ratio (RER) between the fasting and postprandial measurement at baseline (going from 0.89±0.02 to 0.96±0.02, p<0.01), which was not evident at 8 weeks (going from 0.90±0.01 to 0.89±0.01, p=NS). These data suggest that the fraction of ingested carbohydrate that was then synthesized into new fat via DNL would be minimal. In line with this the whole-body and hepatic CO2 data, along with the significant decrease in postprandial RER between baseline and 8 weeks, supports a shift toward FA oxidation (table 2). We calculated net substrate oxidation and found an increase (p<0.001) in the postprandial net fat oxidation rate (g/min) (figure 1E) and a concomitant decrease (p<0.01) in postprandial net carbohydrate oxidation rate (g/min) (figure 1F) after omega-3 supplementation.
Table 2  IHTAG content and fasting and postprandial biochemical characteristics of participants (n=19) taking omega-3 FA

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>8 weeks</th>
</tr>
</thead>
<tbody>
<tr>
<td>IHTAG (%)</td>
<td>7.8±1.6</td>
<td>6.3±1.3*</td>
</tr>
</tbody>
</table>

**Fasting plasma biochemical parameters**

- VLDL-TAG (µmol/L) 1335±57 1069±97*
- VLDL-ApoB (mg/dL) 3.5±0.5 4.6±0.7
- VLDL-TAG/VLDL-ApoB† 34 791±6600 17 657±2945*

**Postprandial plasma biochemical parameters (AUC, time-averaged)**

- Chylomicron-TAG (µmol/L) 564±70 449±52
- VLDL-TAG (µmol/L) 1546±57 1330±79*
- NEFA (µmol/L) 89±21 80±18
- 3OHB (µmol/L) 81.5±11.3 87.3±11.6

**Postprandial 13C-labeled plasma biochemical parameters (AUC, time-averaged)**

- 13C plasma TAG-palmitate (µmol/L) 3.9±0.4 3.3±0.3
- 13C chylomicron-TAG palmitate (µmol/L) 2.9±0.3 2.0±0.2*
- 13C NEFA-palmitate (µmol/L) 0.43±0.04 0.45±0.03
- 13C VLDL-TAG palmitate (µmol/L) 0.87±0.07 0.79±0.05
- Whole-body 13CO2 (µmol/min) 2.8±0.2 3.2±0.2*
- Hepatic 13CO2 (µmol/min) 0.91±0.07 1.0±0.06*
- Respiratory exchange ratio 0.96±0.02 0.89±0.01**

Data expressed as mean±SEM.  
*P<0.05, **P<0.01 baseline vs 8 weeks.  
†Molar ratio.  
AUC, areas under the curve; IHTAG, intrahepatic triacylglycerol; NEFA, nonesterified fatty acids; 3OHB, 3-hydroxybutyrate; TAG, triacylglycerol; VLDL, very low-density lipoprotein.

In vitro cellular data

To further investigate the mechanisms behind the effects observed in vivo in humans we undertook in vitro cellular studies using Huh7 cells and a FA mixture of OPL.

Effect of omega-3 on intracellular TAG content

The addition of omega-3 (EPA+DHA) to OPL resulted in a significant decrease (p<0.01) in intracellular TAG content, with no change in media TAG concentration (figure 2A,B).

Effect of omega-3 on FA synthesis and oxidation

We assessed the effect of OPL and EPA+DHA with OPL only on intracellular DNL using [U-13C]glucose and found a significant reduction (p<0.01) in the proportion of intracellular DNL (as assessed by the incorporation of 13C from glucose into 16:0 ([13C]16:0) when omega-3 (EPA+DHA) were present (figure 2C). We assessed the effects of EPA+DHA on FA oxidation by culturing cells in OPL (where P was [D31]16:0 and looking for the appearance of 2H in media water) with and without EPA+DHA and found a significant (p<0.01) increase in media 2H2O enrichment when cells were cultured in EPA+DHA compared with cells cultured in OPL alone (figure 2D). We observed a significant (p<0.05) increase in the concentration of 3OHB in media, in cells cultured in EPA+DHA compared with OPL alone (figure 2F).

We measured the relative mRNA expression of genes involved in lipogenic and oxidation pathways in Huh7 cells that had been cultured in OPL and OPL+EPA+DHA. Culturing cells with EPA+DHA resulted in significant decreases in expression of some, but not all genes. The presence of EPA+DHA significantly decreased FASN, DGAT2, and SCD mRNA levels compared with OPL alone (online supplementary table 1). In contrast to our finding of increased FA oxidation when using stable-isotopes, there was a significant decrease in the CPT1A mRNA levels with EPA+DHA compared with OPL alone (online supplementary table 1). The data for the expression of ACACB are not presented as the mRNA levels in our cell models were too low to reliably quantify.

DISCUSSION

It is often suggested that increased hepatic DNL is an underlying cause of NAFLD and/or insulin resistance, the latter of which at the level of the liver, leads to continued gluconeogenesis and accelerated DNL. Findings from animal and in vitro work show omega-3 FAs have a hepatocyte-specific effect by downregulating...
Figure 1  The effect of omega-3 FA supplement (omega-3 FA group only) at baseline and 8 weeks on: (A) plasma glucose; (B) plasma insulin; (C) plasma TAG; (D) per cent of DNL-derived FAs in VLDL-TAG; (E) net fat oxidation (baseline and 120 min postprandial) and (F) net carbohydrate oxidation (baseline and 120 min postprandial). Data are presented as means±SEM. DNL, de novo lipogenesis; FA, fatty acid; VLDL, very low-density lipoprotein; TAG, triacylglycerol.
Figure 2  Huh7 cells (n=6 per group) were treated with 200 µM FAs for 48 hours. Cells and media were collected and (A) intracellular TAG content and (B) media TAG content measured. Cells were treated with 200 µM FAs for 48 hours with 13C glucose or D31 palmitate added to the culture media and cells and media were collected for the measurement of the effect of EPA+DHA on: (C) the relative contribution (%) of glucose-derived DNL FAs to intracellular TAG (n=4) and (D) FA oxidation as measured by 2H2O media enrichment (from D31 palmitate, corrected for tracer enrichment) (ppm/mg protein) in cellular media (n=6). Data are presented as means±SEM. *P<0.05; **p<0.01; p<0.001 vs OPL. DNL, de novo lipogenesis; EPA DHA, OPL+EPA+DHA; FA, fatty acid; OPL, oleate, palmitate, linoleate; TAG, triacylglycerol.
the transcription of genes in the lipogenic pathway. If omega-3 FAs attenuate hepatic DNL in vivo in humans, then this may, in part, explain the hypo-TAG and/or IHTAG lowering effect observed with omega-3 supplementation. Findings for the effect omega-3 FAs have on markers of glycemia and FA oxidation are inconsistent. Therefore, we used a combination of human in vivo and in vitro cellular studies, along with stable-isotope methodology, to investigate the effect of 8 weeks supplementation with omega-3 FAs (EPA+DHA) on fasting and postprandial hepatic DNL and FA oxidation. In line with previous work, we found significant decreases in fasting and postprandial plasma TAG concentrations and IHTAG content. Plasma ALT has been reported to be positively associated with IHTAG and the observed decrease in plasma ALT levels after supplementation with omega-3 FA is consistent with a reduction in IHTAG, although a correlation between ALT and IHTAG is not always observed in studies where liver fat has decreased. In addition, we observed significant decreases in fasting and postprandial hepatic DNL and significant increases in dietary FA oxidation and fasting and postprandial plasma glucose concentrations. Moreover, a striking result in the current study was the reversal of a set of canonical metabolic responses to a mixed meal. At baseline, we observed the usual response to a mixed meal, with the suppression of fat oxidation, to preserve dietary FAs for storage, with dietary carbohydrate being utilized instead. After 8 weeks of omega-3 FA supplementation however, the responses to a mixed meal were remarkably different with fat oxidation significantly increasing and carbohydrate utilization significantly decreasing.

**Omega-3 supplementation decreases hepatic DNL**

Although it is often suggested that omega-3 FAs may lower hepatic DNL, this has not been adequately assessed in vivo in humans. In a previous pilot study of patients with NAFLD, we observed that long-term (15–18 months) supplementation with omega-3 FAs decreased fasting hepatic DNL. In the present study, we observed significant decreases in fasting and postprandial hepatic DNL after 8 weeks of omega-3 supplementation. The lack of response in postprandial DNL observed in the current study is notable and extends our previous observations. Hepatic DNL typically increases after consumption of a mixed meal as within the liver, insulin activates the transcription factor sterol regulatory element-binding protein 1c (SREBP-1c) which enhances the transcription of genes required for FA and TAG synthesis. Work by McGarry et al. demonstrated that malonyl-CoA, an intermediate in the DNL pathway, was a potent inhibitor of carnitine-palmitoyltransferase 1. Thus, it is plausible that the physiological importance of the DNL pathway is its contribution to the regulation of FA oxidation via this mechanism, rather than its quantitative contribution to FA supply.

By assessing the effect of omega-3 FAs on glucose-derived DNL in vitro in a relevant hepatocyte model (by using [U\textsuperscript{13}C]glucose), we found the presence of omega-3 (EPA+DHA) attenuated the relative contribution of glucose-derived FAs to intracellular TAG. We also noted the mRNA levels of some, but not all, genes involved in the DNL pathway were attenuated. Rodent work has previously suggested that omega-3 FA supplementation leads to suppression of SREBP1-c when animals are fed a high carbohydrate/glucose diet for 7 days or 5 months. However, Xu et al. noted that after one meal, despite the nuclear protein content of SREBP-1c being decreased, the amount of membrane-anchored precursor SREBP-1c and the abundance of SREBP-1c mRNA were not reduced. Our in vitro model did not recapitulate a lipogenic model that has been used in previous work, where a mixture of glucose and fructose, with no FAs, is present in the culture media. Rather, we cultured the cells in a mixture of nutritional substrates including a physiological mix of FAs and 11 mM glucose and this may, in part, explain the variability in response in the mRNA levels of genes involved in the DNL pathway.

As changes in plasma TAG concentrations may be proportional to the amount of hepatic DNL, it is plausible the decrease in DNL observed here played a role in the observed decreases in VLDL-TAG concentrations, and IHTAG content, through shifting cellular metabolism away from esterification of FA toward oxidation. Although some have reported fasting hepatic DNL to be correlated with IHTAG content and VLDL-TAG secretion rate, we found no associations between change in IHTAG content and change in hepatic DNL. However, Xu et al. noted that after one meal, despite the nuclear protein content of SREBP-1c being decreased, the amount of membrane-anchored precursor SREBP-1c and the abundance of SREBP-1c mRNA were not reduced. Our in vitro model did not recapitulate a lipogenic model that has been used in previous work, where a mixture of glucose and fructose, with no FAs, is present in the culture media. Rather, we cultured the cells in a mixture of nutritional substrates including a physiological mix of FAs and 11 mM glucose and this may, in part, explain the variability in response in the mRNA levels of genes involved in the DNL pathway.

**Supplementation with omega-3 FAs increases plasma glucose concentrations**

Studies have previously found fasting plasma glucose concentrations to increase up to 0.4 mmol/L in individuals without diabetes and over 1.0 mmol/L in individuals with T2D after omega-3 supplementation. In the present study, fasting and postprandial plasma glucose concentrations significantly increased after 8
weeks of supplementation with omega-3 FAs while having no effect on plasma insulin concentrations or markers of whole-body insulin-sensitivity (HOMA-IR). Our findings are in agreement with those of Veleba et al., who reported an increase in fasting and postprandial plasma glucose concentrations, with no change in markers of insulin sensitivity, when metformin treated T2D individuals were supplemented with omega-3 FA (2.8 g EPA+DHA/day) for 24 weeks. The authors proposed the increase in postprandial plasma glucose was due to an increase in carbohydrate and lipid availability, leading to glucose utilization being inhibited by multiple mechanisms in the Randle cycle (eg, inhibition of glucose oxidation at the level of pyruvate dehydrogenase by acetyl-CoA), reflecting peroxisome proliferator-activated receptor (PPAR)α-mediated stimulation of FA oxidation by EPA+DHA. In support of this, we observed a significant decrease in whole-body net carbohydrate oxidation rates after omega-3 supplementation and this observation along with the significant decrease in postprandial hepatic DNL, may, in part, explain the increase in postprandial glucose concentrations. Moreover, it could be speculated that the increase in fasting (and postprandial) blood glucose concentrations was a consequence of shunting glucose out of the liver due to DNL being suppressed by the omega-3 FA. Evidence is sparse for the effects of omega-3 FA on intracellular glucose metabolism and output, in humans in vivo.

**Omega-3 FA supplementation increases whole-body and hepatic FA oxidation but not 3OHB concentrations**

In contrast to others who have assessed net fat oxidation rates using indirect calorimetry, we did not find an increase in the fasting state; however, after consumption of the test meal, we observed a significant increase in postprandial fat oxidation rates after omega-3 supplementation. We used stable-isotope tracer methodology to assess whole-body and hepatic [13C]CO₂ production from recently ingested dietary fat and found both significantly increased after omega-3 supplementation. This observation may, in part, be explained by the significant decrease in postprandial hepatic DNL, which would result in cellular conditions favoring, rather than preventing, FA oxidation. Using stable-isotope methodology in our in vitro studies, we found increased FA oxidation to be evident only when omega-3 (EPA+DHA) were present. Moreover, we observed a significant increase in peroxisomal FA oxidation (as assessed by changes in media acetate levels) and ketogenesis (as measured by media 3OHB) with the presence of omega-3 FAs (EPA+DHA), despite no change or a decrease in the mRNA expression of genes involved in oxidation pathways. The observed increase in media 3OHB is in contrast to our observations in our in vivo study, and those of others, where plasma 3OHB concentrations remained unchanged after omega-3 supplementation. A plausible explanation for the lack of change in plasma 3OHB concentrations is related to glucose sufficiency, meaning oxaloacetate was not being diverted toward gluconeogenesis and could react with acetyl-CoA to form citrate and undergo complete oxidation, rather than the acetyl-CoA being directed toward ketogenesis. Thus, the discrepancy we observed between the in vivo and in vitro data may be explained by glucose sufficiency in vivo, while in the in vitro work, cells were exposed 11 mM glucose in the media glucose, by 48 hours there was virtually no detectable glucose remaining in the media. Therefore, it is plausible that had we change the media every 24 hours rather than 48 hours, the cells would have had sufficient glucose and the increase in media 3OHB would not have been observed.

**Changes in omega-3 FA status with omega-3 FA supplementation**

We found that supplementation with 1.84 g EPA+1.52 g DHA/day for 8 weeks resulted in an increase of ~224% for erythrocyte EPA but only a ~12% increase in erythrocyte DHA, with the degree of change in erythrocyte EPA achieved being inversely associated with baseline levels for EPA but there was no association between baseline and achieved erythrocyte DHA levels. Our observation, of a far larger increase in erythrocyte EPA content than erythrocyte DHA content, is in agreement with previous studies, in which EPA and DHA was given in comparable amounts or when a higher amount of DHA than EPA is consumed. The small change in erythrocyte DHA content compared with erythrocyte EPA content suggests a difference in bioavailability and/or metabolic handling. By supplementing with either EPA or DHA, Grimsgaard et al. demonstrated that with DHA supplementation, the content of both EPA and DHA in serum phospholipids increased, and suggested that some of the observed increase in EPA was due to retroconversion of DHA to EPA. They also noted that with pure EPA supplementation, there was an increase in erythrocyte EPA content and a decrease in erythrocyte DHA content. Given these observations and the recent findings that ischemic events, including CVD, were significantly lower among individuals with elevated plasma TAG taking 4 g/day of a highly purified ethyl ester (Icosapent ethyl) than those taking a placebo, it is of interest to determine the effects of bioavailability (and mechanism of action) of both EPA and DHA. Recent evidence from the Phase III STRENGTH trial suggests that when EPA+DHA are given as carboxylic acids (Epanova), they provide no benefit in patients with mixed dyslipidemia who were at increased risk of CVD.

**Limitations**

We studied only men; therefore, it would be of interest to study the effect of omega-3 supplementation on both premenopausal and postmenopausal women to determine if there are sex-specific effects. We did not assess VLDL-TAG production or clearance rates. Omega-3 supplementation has been reported to decrease VLDL ApoB production, but not catabolism and VLDL-TAG. 

---

1. Grimsgaard et al.
2. Veleba et al.
3. Epanova
secretion rates but has negligible effect on plasma ApoCIII concentrations, which regulate VLDL clearance. For logistical reasons, we assessed IHTAG and hepatic DNL and FA oxidation only in the omega-3 and not the placebo group; based on previous data, it is likely there would have been minimal changes in these parameters but it would be of interest to confirm this. We undertook in vitro cellular work to gain mechanistic insight; however, we cannot confirm whether both EPA and DHA were needed to have the observed effects, as the cells were exposed to both FAs; it would be of interest to determine the effects of EPA and DHA individually. Although we asked participants to maintain their habitual diet, we did not assess or control dietary intakes and thus it is plausible that the suppression in hepatic DNL resulted in a greater increase in plasma glucose concentrations in individuals who were consuming a high carbohydrate diet.

CONCLUSION

Taken together, our data demonstrate that omega-3 FAs (as EPA+DHA) are required to significantly alter intrahepatic DNL and FA oxidation, through potentially multiple intrahepatic mechanisms (figure 3) and the changes reported here may underpin decreases in plasma TAG concentrations and IHTAG content. However, with the notable decrease in fasting and postprandial hepatic DNL and postprandial carbohydrate oxidation, and significant increase in fasting and postprandial plasma glucose concentrations, consideration is required for the long-term effects of attenuating hepatic DNL and potentially elevating circulating glucose concentrations on other intrahepatic and extrahepatic metabolic pathways.

Twitter Leanne Hodson @Hodson_Group

Acknowledgements We thank Louise Dennis, Rachel Craven-Todd and CRU staff for excellent nursing provision, Marje Gilbert for technical assistance, Sandy Humphreys for helpful statistical advice and technical assistance and Ross Milne for antibodies. We thank the volunteers from the Oxford Biobank (http://www.oxfordbiobank.org.uk) for their participation in this recall study. The Oxford BioBank and Oxford Bioresource are funded by the NIHR Oxford Biomedical Research Centre (BRC).

Contributors LH obtained funding and designed the study. LH, CJG, CP, CAC, PJG, TC and MP conducted the research. CJG, CP, PJG and LH analyzed the data. CJG, CP, FK and LH wrote the paper. FK and LH helped with data interpretation and revisions of the manuscript. LH had primary responsibility for final content. All authors read and approved the final manuscript.

Funding This study was funded by the British Heart Foundation FS/11/18/28633 and FS/15/56/31645 both awarded to LH.
Metabolism

Disclaimer The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social care.

Competing interests MP is a shareholder in Perspective Diagnostics, a University of Oxford spin out company.

Patient consent for publication Not required.

Ethics approval The study was approved by Portugal Clinical Research Ethics Committee (12/SC/0267) and all subjects gave written informed consent.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information. All relevant data are included in the manuscript.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

ORCID iDs

Freddik Karpe http://orcid.org/0000-0002-2751-1770
Leanne Hodson http://orcid.org/0000-0002-2048-6526

REFERENCES


